Literature DB >> 20875851

Poststress treatment with PNU282987 can rescue SH-SY5Y cells undergoing apoptosis via α7 nicotinic receptors linked to a Jak2/Akt/HO-1 signaling pathway.

Esther Parada1, Javier Egea, Alejandro Romero, Laura del Barrio, Antonio G García, Manuela G López.   

Abstract

Most neuroprotection studies with nicotinic agonists have shown efficacy when given before the stressor. Here we have investigated whether the α7 nicotinic acetylcholine receptor (nAChR) agonist PNU282987 can prevent cell death once the cells have already undergone an oxidative stress. The combination of rotenone (30 μM) plus oligomycin A (10 μM) (rot/oligo) has been used as an in vitro model of mitochondrial ROS production. SH-SY5Y cells incubated with rot/oligo for 8h and left for another 16 h in MEM/F-12 experienced 30% apoptotic cell death. Under these experimental conditions, PNU282987 administered after rot/oligo (PST/PNU) prevented cell death in a concentration-dependent manner. Co-incubation of PNU282987 with 100 nM methyllycaconitine (a selective α7 nAChR antagonist), 10 μM mecamylamine (a nonselective nAChR antagonist), 3 μM LY294002 (a PI3K inhibitor), or 10 μM AG490 (a Jak2 inhibitor) prevented the protection afforded by PST/PNU. Moreover, the increase in ROS, active caspase-3, and apoptosis caused by rot/oligo was also prevented by PST/PNU. Furthermore, PNU282987 increased the expression of heme oxygenase-1 (HO-1), a critical cell defense enzyme against oxidative stress; this increase was prevented by AG490 or LY294002. The HO-1 inhibitor Sn(IV) protoporphyrin-IX also inhibited the PST/PNU protecting effects. These results suggest that activation of α7 nAChR linked to the Jak2/PI3K/Akt cascade induces the antioxidant enzyme HO-1 to provide neuroprotection.
Copyright © 2010 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20875851     DOI: 10.1016/j.freeradbiomed.2010.09.017

Source DB:  PubMed          Journal:  Free Radic Biol Med        ISSN: 0891-5849            Impact factor:   7.376


  20 in total

Review 1.  Potential Therapeutic Application for Nicotinic Receptor Drugs in Movement Disorders.

Authors:  Maryka Quik; James T Boyd; Tanuja Bordia; Xiomara Perez
Journal:  Nicotine Tob Res       Date:  2019-02-18       Impact factor: 4.244

2.  Functional Consequences of CHRNA7 Copy-Number Alterations in Induced Pluripotent Stem Cells and Neural Progenitor Cells.

Authors:  Madelyn A Gillentine; Jiani Yin; Aleksandar Bajic; Ping Zhang; Steven Cummock; Jean J Kim; Christian P Schaaf
Journal:  Am J Hum Genet       Date:  2017-11-09       Impact factor: 11.025

Review 3.  The parasympathetic nervous system in the quest for stroke therapeutics.

Authors:  Cletus Cheyuo; Asha Jacob; Rongqian Wu; Mian Zhou; Gene F Coppa; Ping Wang
Journal:  J Cereb Blood Flow Metab       Date:  2011-03-02       Impact factor: 6.200

4.  Neuroprotective effects of E-PodoFavalin-15999 (Atremorine®).

Authors:  Alejandro Romero; Esther Parada; Laura González-Lafuente; Victor Farré-Alins; Eva Ramos; Ramón Cacabelos; Javier Egea
Journal:  CNS Neurosci Ther       Date:  2017-03-30       Impact factor: 5.243

Review 5.  Alpha7 nicotinic receptors as therapeutic targets for Parkinson's disease.

Authors:  Maryka Quik; Danhui Zhang; Matthew McGregor; Tanuja Bordia
Journal:  Biochem Pharmacol       Date:  2015-06-18       Impact factor: 5.858

6.  The microglial α7-acetylcholine nicotinic receptor is a key element in promoting neuroprotection by inducing heme oxygenase-1 via nuclear factor erythroid-2-related factor 2.

Authors:  Esther Parada; Javier Egea; Izaskun Buendia; Pilar Negredo; Ana C Cunha; Silvia Cardoso; Miguel P Soares; Manuela G López
Journal:  Antioxid Redox Signal       Date:  2013-02-25       Impact factor: 8.401

Review 7.  Roles of the Functional Interaction between Brain Cholinergic and Dopaminergic Systems in the Pathogenesis and Treatment of Schizophrenia and Parkinson's Disease.

Authors:  Srijan Acharya; Kyeong-Man Kim
Journal:  Int J Mol Sci       Date:  2021-04-21       Impact factor: 5.923

8.  Molecular Mechanisms Regulating LPS-Induced Inflammation in the Brain.

Authors:  Olena Lykhmus; Nibha Mishra; Lyudmyla Koval; Olena Kalashnyk; Galyna Gergalova; Kateryna Uspenska; Serghiy Komisarenko; Hermona Soreq; Maryna Skok
Journal:  Front Mol Neurosci       Date:  2016-03-08       Impact factor: 5.639

Review 9.  Emerging preclinical pharmacological targets for Parkinson's disease.

Authors:  Sandeep Vasant More; Dong-Kug Choi
Journal:  Oncotarget       Date:  2016-05-17

Review 10.  Vagus nerve stimulation in ischemic stroke: old wine in a new bottle.

Authors:  Peter Y Cai; Aakash Bodhit; Roselle Derequito; Saeed Ansari; Fawzi Abukhalil; Spandana Thenkabail; Sarah Ganji; Pradeepan Saravanapavan; Chandana C Shekar; Sharatchandra Bidari; Michael F Waters; Vishnumurthy Shushrutha Hedna
Journal:  Front Neurol       Date:  2014-06-24       Impact factor: 4.003

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.